---
annotation-target: s41375-022-01687-x.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-13T00:55:25.601Z","text":"微环境","updated":"2022-09-13T00:55:25.601Z","document":{"title":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","link":[{"href":"urn:x-pdf:de6b365d862700c1ffe9407f2650cc14"},{"href":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf"}],"documentFingerprint":"de6b365d862700c1ffe9407f2650cc14"},"uri":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","selector":[{"type":"TextPositionSelector","start":80,"end":86},{"type":"TextQuoteSelector","exact":"niche-","prefix":"ne kinase 2b inhibition reverts ","suffix":"associatedresistance to tyrosine"}]}]}
>```
>%%
>*%%PREFIX%%ne kinase 2b inhibition reverts%%HIGHLIGHT%% ==niche-== %%POSTFIX%%associatedresistance to tyrosine*
>%%LINK%%[[#^bvl6h5h8t5h|show annotation]]
>%%COMMENT%%
>微环境
>%%TAGS%%
>
^bvl6h5h8t5h


>%%
>```annotation-json
>{"created":"2022-09-13T00:56:52.059Z","updated":"2022-09-13T00:56:52.059Z","document":{"title":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","link":[{"href":"urn:x-pdf:de6b365d862700c1ffe9407f2650cc14"},{"href":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf"}],"documentFingerprint":"de6b365d862700c1ffe9407f2650cc14"},"uri":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","selector":[{"type":"TextPositionSelector","start":707,"end":1474},{"type":"TextQuoteSelector","exact":". We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin(LPXN), a regulator of cell migration and adhesion, was induced during early resistance development, alongside the tyrosine kinasePTK2B which phosphorylated LPXN. Resistant cells differed in cell adhesion and migration, indicating altered niche interactions.PTK2B and LPXN were highly expressed in leukemic stem cells in FLT3-ITD patients. PTK2B/FAK inhibition abrogated resistance-associated phenotypes, such as enhanced cell migration. Altered pathways in resistant cells, assessed by nascent proteomics, werelargely reverted upon PTK2B/FAK inhibition. PTK2B/FAK inhibitors PF-431396 and defactinib synergized with different TKIs ordaunorubicin in FLT3-mutated AML. ","prefix":"opsfrequently with poor outcomes","suffix":"Midostaurin-resistant and AML ce"}]}]}
>```
>%%
>*%%PREFIX%%opsfrequently with poor outcomes%%HIGHLIGHT%% ==. We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin(LPXN), a regulator of cell migration and adhesion, was induced during early resistance development, alongside the tyrosine kinasePTK2B which phosphorylated LPXN. Resistant cells differed in cell adhesion and migration, indicating altered niche interactions.PTK2B and LPXN were highly expressed in leukemic stem cells in FLT3-ITD patients. PTK2B/FAK inhibition abrogated resistance-associated phenotypes, such as enhanced cell migration. Altered pathways in resistant cells, assessed by nascent proteomics, werelargely reverted upon PTK2B/FAK inhibition. PTK2B/FAK inhibitors PF-431396 and defactinib synergized with different TKIs ordaunorubicin in FLT3-mutated AML.== %%POSTFIX%%Midostaurin-resistant and AML ce*
>%%LINK%%[[#^z5lh3g5al8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^z5lh3g5al8


>%%
>```annotation-json
>{"created":"2022-09-13T01:00:32.605Z","text":"FLT3抑制剂\n30%的急性髓系白血病(acute myeloid leukemia, AML)患者存在FMS样酪氨酸激酶3(FMS-like tyrosine kinase 3, FLT3)基因突变，其中近1/4存在内部串联重复(internal tandem duplication, ITD)。FLT3-ITD突变会增加复发和预后不良的风险。FLT3抑制剂可诱导FLT3突变原始粒细胞的终末分化和对该细胞的直接细胞毒作用[176]。\n\nFLT3抑制剂包括：\n\n●索拉非尼、来他替尼(lestaurtinib)、米哚妥林(第一代多激酶抑制剂)。\n\n●奎扎替尼(quizartinib)、克莱拉尼(crenolanib)、吉瑞替尼(gilteritinib)(新一代抑制剂)；相比第一代药物，这类药物效果更强、脱靶效应更少。","updated":"2022-09-13T01:00:32.605Z","document":{"title":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","link":[{"href":"urn:x-pdf:de6b365d862700c1ffe9407f2650cc14"},{"href":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf"}],"documentFingerprint":"de6b365d862700c1ffe9407f2650cc14"},"uri":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","selector":[{"type":"TextPositionSelector","start":1474,"end":1485},{"type":"TextQuoteSelector","exact":"Midostaurin","prefix":"unorubicin in FLT3-mutated AML. ","suffix":"-resistant and AML cells co-cult"}]}]}
>```
>%%
>*%%PREFIX%%unorubicin in FLT3-mutated AML.%%HIGHLIGHT%% ==Midostaurin== %%POSTFIX%%-resistant and AML cells co-cult*
>%%LINK%%[[#^a8gjxm3heco|show annotation]]
>%%COMMENT%%
>FLT3抑制剂
>30%的急性髓系白血病(acute myeloid leukemia, AML)患者存在FMS样酪氨酸激酶3(FMS-like tyrosine kinase 3, FLT3)基因突变，其中近1/4存在内部串联重复(internal tandem duplication, ITD)。FLT3-ITD突变会增加复发和预后不良的风险。FLT3抑制剂可诱导FLT3突变原始粒细胞的终末分化和对该细胞的直接细胞毒作用[176]。
>
>FLT3抑制剂包括：
>
>●索拉非尼、来他替尼(lestaurtinib)、米哚妥林(第一代多激酶抑制剂)。
>
>●奎扎替尼(quizartinib)、克莱拉尼(crenolanib)、吉瑞替尼(gilteritinib)(新一代抑制剂)；相比第一代药物，这类药物效果更强、脱靶效应更少。
>%%TAGS%%
>#突变型FLT3的抑制剂 — AML常伴有FLT3突变，包括跨膜区ITD(FLT3-ITD)或TKD的活化环改变(FLT3-TKD)。白血病细胞表面FLT3-ITD分子的高频突变与预后不良和缓解期短有关。  我们建议对FLT3突变的AML患者在7+3方案的基础上加用米哚妥林，相比单用7+3方案可以改善结局且毒性仅轻微增加。
^a8gjxm3heco


>%%
>```annotation-json
>{"created":"2022-09-13T01:10:50.892Z","updated":"2022-09-13T01:10:50.892Z","document":{"title":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","link":[{"href":"urn:x-pdf:de6b365d862700c1ffe9407f2650cc14"},{"href":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf"}],"documentFingerprint":"de6b365d862700c1ffe9407f2650cc14"},"uri":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","selector":[{"type":"TextPositionSelector","start":3092,"end":3851},{"type":"TextQuoteSelector","exact":"One well-established concept of chemotherapy-resistance inleukemia is cell adhesion-mediated drug resistance (CAM-DR).Early on, it has been shown that AML cells are less prone to drug-induced apoptosis upon co-cultivation with a human bonemarrow stromal cell line (HS-5) [4]. Besides their direct involve-ment in mediating intercellular binding or the interaction with theextracellular matrix, cell adhesion molecules (CAMs) as single-passtransmembrane molecules play a central role in translatingexternal stimuli into intracellular signaling cascades [5]. CAMsare widely expressed on leukemia cells and cells of the bonemarrow niche and have been shown to play an important role inLSC homeostasis, their protection, and their escape from standardchemotherapy","prefix":"resis-tance are urgently needed.","suffix":" [6, 7].The focal adhesion prote"}]}]}
>```
>%%
>*%%PREFIX%%resis-tance are urgently needed.%%HIGHLIGHT%% ==One well-established concept of chemotherapy-resistance inleukemia is cell adhesion-mediated drug resistance (CAM-DR).Early on, it has been shown that AML cells are less prone to drug-induced apoptosis upon co-cultivation with a human bonemarrow stromal cell line (HS-5) [4]. Besides their direct involve-ment in mediating intercellular binding or the interaction with theextracellular matrix, cell adhesion molecules (CAMs) as single-passtransmembrane molecules play a central role in translatingexternal stimuli into intracellular signaling cascades [5]. CAMsare widely expressed on leukemia cells and cells of the bonemarrow niche and have been shown to play an important role inLSC homeostasis, their protection, and their escape from standardchemotherapy== %%POSTFIX%%[6, 7].The focal adhesion prote*
>%%LINK%%[[#^oeawtsw7ns|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^oeawtsw7ns


>%%
>```annotation-json
>{"created":"2022-09-13T01:15:05.785Z","updated":"2022-09-13T01:15:05.785Z","document":{"title":"Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML","link":[{"href":"urn:x-pdf:de6b365d862700c1ffe9407f2650cc14"},{"href":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf"}],"documentFingerprint":"de6b365d862700c1ffe9407f2650cc14"},"uri":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/s41375-022-01687-x.pdf","selector":[{"type":"TextPositionSelector","start":16964,"end":17647},{"type":"TextQuoteSelector","exact":"All statistical tests were performed using R version 4.5 and R-studio version1.13 or GraphPad Prism version 9.3.1.Values are presented as mean ± s.d. of replicates. Two-tailed Student’stest was used to determine statistical significance unless stated otherwise.Nonlinear-regression analysis was performed for calculation of IC50 values.p-values < 0.05 were considered to be statistically significant. Synergyscores were computed according to the Bliss Independence Model and theZero Interaction Potency Model (ZIP) [11] with the synergyfinderR-package version 2.4.13 [12]. Log-rank (Mantel-Cox) test was used toevaluate Kaplan–Meier time to leukemia-symptom related endpointanalysis.","prefix":"oRender.com.Statistical analysis","suffix":"RESULTSLPXN is induced during ac"}]}]}
>```
>%%
>*%%PREFIX%%oRender.com.Statistical analysis%%HIGHLIGHT%% ==All statistical tests were performed using R version 4.5 and R-studio version1.13 or GraphPad Prism version 9.3.1.Values are presented as mean ± s.d. of replicates. Two-tailed Student’stest was used to determine statistical significance unless stated otherwise.Nonlinear-regression analysis was performed for calculation of IC50 values.p-values < 0.05 were considered to be statistically significant. Synergyscores were computed according to the Bliss Independence Model and theZero Interaction Potency Model (ZIP) [11] with the synergyfinderR-package version 2.4.13 [12]. Log-rank (Mantel-Cox) test was used toevaluate Kaplan–Meier time to leukemia-symptom related endpointanalysis.== %%POSTFIX%%RESULTSLPXN is induced during ac*
>%%LINK%%[[#^fx51enqvb4o|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^fx51enqvb4o
